Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-8427 in Complicated Urinary Tract Infection
NCT06569056Phase 3Completed
- Sponsor
- Hengrui
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HRS-8427 in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Hengrui. Primary endpoint: Composite Response of Microbiological Eradication and Clinical Response. Started Sep 2024; status: completed.
02
Drugs
HRS-8427
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT06569056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569056.